Evaluation of Current and New Biomarkers in Severe Preeclampsia: A Microarray Approach Reveals the VSIG4 Gene as a Potential Blood Biomarker

Textoris, Julien; Ivorra, Delphine; Amara, Amira Ben; Sabatier, Florence; Ménard, Jean-Pierre; Heckenroth, H.; Bretelle, Florence; Mège, Jean‐Louis

doi:10.1371/journal.pone.0082638

Cited by 38 publications

(50 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rapidly developing hypertensive conditions such as pre-eclampsia, studies can be performed at different time points to explore changes in regulation and also with regard to prediction of the development of these conditions. A number of such studies in placental tissue and in peripheral blood have been performed and highlight differential regulation of genes, many of which are involved in immune mechanisms 23, 24, 25…”

Section: Transcriptomicsmentioning

confidence: 99%

The Future of “Omics” in Hypertension

Currie

Delles

2017

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Despite decades of research and clinical practice, the pathogenesis of hypertension remains incompletely understood, and blood pressure is often suboptimally controlled. “Omics” technologies allow the description of a large number of molecular features and have the potential to identify new factors that contribute to blood pressure regulation and how they interact. In this review, we focus on the potential of genomics, transcriptomics, proteomics, and metabolomics and explore their roles in unraveling the pathophysiology and diagnosis of hypertension, the prediction of organ damage and treatment response, and monitoring treatment effect. Substantial progress has been made in the area of genomics, in which genome-wide association studies have identified > 50 blood pressure–related, single-nucleotide polymorphisms, and sequencing studies (especially in secondary forms of hypertension) have discovered novel regulatory pathways. In contrast, other omics technologies, despite their ability to provide detailed insights into the physiological state of an organism, have only more recently demonstrated their impact on hypertension research and clinical practice. The majority of current proteomic studies focus on organ damage resulting from hypertension and may have the potential to help us understand the link between blood pressure and organ failure but also serve as biomarkers for early detection of cerebrovascular or coronary disease. Examples include signatures for early detection of left ventricular dysfunction or albuminuria. Metabolomic studies have the potential to integrate environmental and intrinsic factors and are particularly suited to monitor the response to treatment. We discuss examples of omics studies in hypertension and explore the challenges related to these novel technologies.

show abstract

Section: Transcriptomicsmentioning

confidence: 99%

The Future of “Omics” in Hypertension

Currie

Delles

2017

Canadian Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…In a similar microarray examination of maternal lymphocytes, a different pattern was noted between PE cases and controls, mainly related to complement and protein translation [105] . When the PE cases were stratified into severe ePE and non-severe lPE, eight genes were found to be specifically upregulated in the former.…”

Section: Multiple Independent or Linked Etiologies – What Are The Impmentioning

confidence: 86%

Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?

Hahn

Lapaire

Than

2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

The past decade saw the advent of a number of promising biomarkers to detect pregnancies at risk for preeclampsia (PE), the foremost being those associated with an imbalance of angiogenic factors. In late pregnancy, these are useful for the detection of imminent cases of PE, while earlier they were more predictive for early- than late-onset PE. This suggests that there may be fundamental differences between the underlying pathology of these two PE forms. Therefore, it is possible that such a biological premise may limit the development of biomarkers that will permit the efficacious detection of both early- and late-onset PE via an analysis of first-trimester maternal blood samples. Consequently, a significant increase in our understanding of the underlying pathology of PE, using a variety of approaches ranging from systems biology to animal models, will be necessary in order to overcome this obstacle.

show abstract

“…Many biomarkers for the diagnosis of preeclampsia have been reported (Textoris et al 2013;Maynard et al 2013;Palominos et al 2014). However, these biomarkers are still far from for clinical usage.…”

Section: Discussionmentioning

confidence: 99%

Low Serum Levels of ABCA1, an ATP-Binding Cassette Transporter, Are Predictive of Preeclampsia

Liu

Zhang

Min³

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Preeclampsia is a pregnancy-specific disorder characterized by hypertension and proteinuria, but the exact cause of preeclamptic hypertension remains unknown. ATP-binding cassette subfamily A member 1 (ABCA1) reverses cholesterol transport and eliminates excess cholesterol from tissues, whereas higher levels of cholesterol may lead to hypertension. Thus, ABCA1 affects the blood lipid profile. We have hypothesized that serum ABCA1 levels may influence the onset of hypertension and increase the risk of preeclampsia. To test this hypothesis, we measured serum ABCA1 levels in 50 normal pregnancies, 36 preeclamptic pregnancies, and 24 small-for-gestational-age (SGA) pregnancies during three trimesters. We also measured the concentrations of serum ABCA1 in non-pregnant women (n = 60), showing its normal ranges of 0.16 to 0.52 ng/ml. Importantly, the serum levels of ABCA1 were similar among non-pregnant women, normal pregnancies and SGA pregnancies. In contrast, the serum ABCA1 levels were significantly lower in preeclamptic pregnancies (0.06 ± 0.03 ng/ml) than those in non-pregnant women, and normal and SGA pregnancies (P < 0.05). Low serum ABCA1 levels were associated with the increases in the concentrations of blood lipid (low density lipoprotein cholesterol, total cholesterol and triglycerides) and with the decrease in the concentration of high-density lipoprotein cholesterol (P < 0.01), all of which may contribute to the onset of hypertension and eventually preeclampsia. Moreover, the preeclamptic pregnancy was diagnosed with high sensitivity from the nulliparous pregnancies if the cutoff value for serum ABCA1 was 0.06 ng/ml. Thus, low serum levels of ABCA1 are predictive of preeclampsia.

show abstract

Evaluation of Current and New Biomarkers in Severe Preeclampsia: A Microarray Approach Reveals the VSIG4 Gene as a Potential Blood Biomarker

Cited by 38 publications

References 49 publications

The Future of “Omics” in Hypertension

The Future of “Omics” in Hypertension

Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?

Low Serum Levels of ABCA1, an ATP-Binding Cassette Transporter, Are Predictive of Preeclampsia

Contact Info

Product

Resources

About